Press Releases

FORT WORTH, Texas--(BUSINESS WIRE)-- Crestline Summit, the multi-strategy hedge fund division of Crestline Investors, Inc., today announced the appointment of Brian Peller as Chief Operating Officer. In this role, he will oversee middle and back-office operations, legal and compliance, accounting, and technology functions for the division.

Peller most recently served as Chief Operating Officer of Alliance Bernstein’s Multi-Asset Solutions business for five... (continue reading...)

HyperPlay takes its collaboration with MetaMask to next level with launch of new games directory available within MetaMask Portfolio

FORT WORTH, Texas--(BUSINESS WIRE)-- HyperPlay, the premier web3-enabled game store dedicated to ending the de-platforming of web3 games while improving the user experience around web3 gaming, today announces a new development in collaboration with MetaMask, the leading digital asset wallet and gateway to the decentralized web. A... (continue reading...)

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Global Life Inc. (“Global Life”) (NYSE: GL) for potential violations of the federal securities laws. The firm’s investigation is in connection with reports that Global Life executives ignored extensive allegations of insurance fraud.

If you suffered a loss of more than $50,000 in Global Life securities, and... (continue reading...)

CCW Digital's Latest Market Study Focuses On The Recent Decline Of Customer Experience Despite Increased Use Of AI

NEW YORK and LAS VEGAS, June 6, 2024 /PRNewswire/ -- Today, CCW Digital, a division of Customer Management Practice (CMP), a leading market intelligence firm for the customer management industry, released the results of its latest market study on CX Trends, Challenges, and Opportunities during CMP's flagship Customer Contact Week taking place at Caesars... (continue reading...)

• New science for cancer therapy drives powerful value proposition
• Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial
• Funding of more than $12M year-to-date, including $7.4 million in Q2’24 so far
• Secured continued insider investment through independent board members’ participation in private placement equity financings
• Newest data shows THIO’s strong outperformance against standard-of-care treatments in non-small cell lung... (continue reading...)